CN113226350B - 皮肤病治疗剂 - Google Patents

皮肤病治疗剂 Download PDF

Info

Publication number
CN113226350B
CN113226350B CN201980060757.0A CN201980060757A CN113226350B CN 113226350 B CN113226350 B CN 113226350B CN 201980060757 A CN201980060757 A CN 201980060757A CN 113226350 B CN113226350 B CN 113226350B
Authority
CN
China
Prior art keywords
polypeptide
seq
administered
skin
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980060757.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113226350A (zh
Inventor
G·维勒缇
B·P·艾姆毕姆伯
L·卡尔扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN113226350A publication Critical patent/CN113226350A/zh
Application granted granted Critical
Publication of CN113226350B publication Critical patent/CN113226350B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980060757.0A 2018-09-17 2019-09-17 皮肤病治疗剂 Active CN113226350B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18194930.6 2018-09-17
EP18194930 2018-09-17
EP18203665.7 2018-10-31
EP18203665 2018-10-31
PCT/EP2019/074767 WO2020058217A1 (en) 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders

Publications (2)

Publication Number Publication Date
CN113226350A CN113226350A (zh) 2021-08-06
CN113226350B true CN113226350B (zh) 2024-09-10

Family

ID=67989007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980060757.0A Active CN113226350B (zh) 2018-09-17 2019-09-17 皮肤病治疗剂

Country Status (11)

Country Link
US (2) US20220064243A1 (https=)
EP (1) EP3852785A1 (https=)
JP (2) JP2022502359A (https=)
KR (1) KR20210061388A (https=)
CN (1) CN113226350B (https=)
AU (1) AU2019343514B2 (https=)
BR (1) BR112021003820A2 (https=)
CA (1) CA3111158A1 (https=)
MA (1) MA53636A (https=)
MX (1) MX2021002983A (https=)
WO (1) WO2020058217A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536229A (ja) * 2020-07-27 2023-08-24 ヒューマン セル カンパニー Ｎｇｆバリアント、産生、組成物、及び治療的使用
CA3207296A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
WO2010128519A1 (en) 2009-05-04 2010-11-11 Kumar C Jairaj A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Generini s等.Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases.exp clin endocrinol diabetes.2004,第第112卷卷第542-544页. *

Also Published As

Publication number Publication date
JP2022502359A (ja) 2022-01-11
BR112021003820A2 (pt) 2021-05-25
AU2019343514A1 (en) 2021-04-15
CA3111158A1 (en) 2020-03-26
EP3852785A1 (en) 2021-07-28
JP2025125558A (ja) 2025-08-27
KR20210061388A (ko) 2021-05-27
MA53636A (fr) 2021-12-22
AU2019343514B2 (en) 2025-09-25
MX2021002983A (es) 2021-05-14
WO2020058217A1 (en) 2020-03-26
US20220064243A1 (en) 2022-03-03
CN113226350A (zh) 2021-08-06
US20250277010A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
US20250277010A1 (en) Agent for treatment of dermatological disorders
JP6846063B2 (ja) 異常な皮膚瘢痕化の治療
AU2019272030A1 (en) Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor
CN100509055C (zh) 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
US12214024B2 (en) Use of APC analogue for wound healing
US20220062381A1 (en) Methods for promoting wound healing and hair growth
RU2799211C2 (ru) Средство для лечения дерматологических заболеваний
HK40047629A (zh) 皮肤病治疗剂
HK40047629B (zh) 皮肤病治疗剂
RU2812055C1 (ru) Агент для использования при лечении или профилактике офтальмологических расстройств
WO2022204331A1 (en) Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
HK1230520B (zh) Apc类似物用於创伤癒合的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047629

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant